Massive study catalogues GLP-1's many benefits & risks, Medicare targets Ozempic for price cuts, high-dose Wegovy shows promising weight loss results, and more!
The Gut Punch Weekly #4
Massive study catalogues GLP-1's many benefits & risks, Medicare targets Ozempic for price cuts, high-dose Wegovy shows promising weight loss results, and more!